Search Results

Developing risk models and subtypes of autophagy-associated LncRNAs for enhanced prognostic prediction and precision in therapeutic approaches for liver cancer patients.

• Authors : LU ZHANG; JINGUO CHU; YUSHAN YU

Subjects: THERAPEUTICS; LIVER cancer; CANCER patients

• Source: Oncology Research; 2024, Vol. 32 Issue 4, p703-716, 14p

Record details

Agricola

Record details

中医外治法治疗肝癌晚期常见并发症的新思路.

• Authors : 潘沙沙¹; 郑煥填¹; 占伯林¹

Subjects: *LIVER cancer patients; *CANCER pain treatment; *CHINESE medicine

• Source: Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi. Dec2017, Vol. 33 Issue 12, p2429-2432. 4p.

Record details

瑞戈非尼治疗肝细胞癌的研究进展.

• Authors : 陈卫波¹; 蔡辉华¹; 杨岳¹

Subjects: *LIVER cancer patients; *LIVER cancer; *REGORAFENIBUNITED States. Food & Drug Administration

• Source: Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi. Dec2017, Vol. 33 Issue 12, p2425-2428. 4p.

Record details

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

• Authors : Masatoshi Kudo; Jassem, Jacek; Blanc, Jean Frederic

Subjects: LIVER cancer; SORAFENIB; VASCULAR endothelial growth factor antagonists

• Source: Lancet. 3/24/2018, Vol. 391 Issue 10126, p1163-1173. 11p. 3 Charts, 3 Graphs.

Record details

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

• Authors : Bruix, Jordi; Shukui Qin; Merle, Philippe

Subjects: REGORAFENIB; SORAFENIB; LIVER cancer

• Source: Lancet. 1/7/2017, Vol. 389 Issue 10064, p56-66. 11p. 1 Diagram, 2 Charts, 1 Graph.

Record details

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

• Authors : Abou-Alfa, G. K.; Meyer, T.; Cheng, A.-L.

Subjects: LIVER cancer patients; PROTEIN-tyrosine kinases; VASCULAR endothelial growth factors

• Source: New England Journal of Medicine. 7/5/2018, Vol. 379 Issue 1, p54-63. 10p.

Record details

Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial.

• Authors : Hatooka, Masahiro¹; Kawaoka, Tomokazu¹ ; Aikata, Hiroshi¹

Subjects: *LIVER cancer patients; *HEPATIC arterial infusion chemotherapy; *CANCER chemotherapy

• Source: BMC Cancer. 6/4/2018, Vol. 18 Issue 1, p1-10. 10p. 2 Diagrams, 4 Charts, 3 Graphs.

Record details

Combining albumin‐bilirubin score with future liver remnant predicts post‐hepatectomy liver failure in HBV‐associated HCC patients.

• Authors : Zou, Heng¹; Wen, Yu¹; Yuan, Kun¹

Subjects: *LIVER cancer patients; *ALBUMINS; *BILIRUBIN

• Source: Liver International. Mar2018, Vol. 38 Issue 3, p494-502. 9p. 4 Charts, 4 Graphs.

Record details

The rationale for targeting TGF-β in chronic liver diseases.

• Authors : Giannelli, Gianluigi; Mikulits, Wolfgang; Dooley, Steven

Subjects: TRANSFORMING growth factors; HEPATOCYTE growth factor; LIVER cancer patients

• Source: European Journal of Clinical Investigation. Apr2016, Vol. 46 Issue 4, p349-361. 13p.

Record details